Sparsentan, a novel dual-action drug, shows promise for the treatment of focal segmental glomerulosclerosis (FSGS), a kidney disease for which no FDA-approved pharmacotherapy exists, researchers reported at the American Society of Nephrology's 2016 Kidney Week meeting.
Medical expulsive therapy with alpha blockers can promote clearance of ureteric stones 5 mm and larger, a new systematic review and meta-analysis confirms.
Managing complaints can be a way to make or break your patient relationships and online reputation.
A reduced sodium diet may improve residual albuminuria in chronic kidney disease (CKD) patients free of diabetes who are treated with a single renin-angiotensin-aldosterone system (RAAS) inhibitor.
HIV-infected men on antiretroviral therapy have a lower incidence of prostate cancer (PCa) compared with those in the general population, new study findings suggest.
Get a sneak peek of happenings at the American Society of Nephrology's Kidney Week 2016.
Partial nephrectomy (PN) and radical nephrectomy (RN) are associated with similar survival outcomes among elderly patients, a new study suggests.
Practices benefit from cost savings and easy access to patient records, but information breaches are still possible.
The FDA has approved removal of a boxed warning from the patiromer (Veltassa) drug label related to the timing of drug administration.
Omega-3 fatty acids may explain the obesity paradox observed in patients with advanced chronic kidney disease (CKD), according to study findings presented at the American Society of Nephrology's 2016 Kidney Week meeting.
Increased clinical research has been focused on the sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the management of type 2 diabetes.
Access our job board to view over 1,000 job openings throughout the US.
Tell us about your social media habits for a chance to win a free gift card.